InvestorsHub Logo
Followers 29
Posts 9421
Boards Moderated 0
Alias Born 04/30/2006

Re: opportunityknocking post# 27303

Monday, 09/20/2010 11:49:24 AM

Monday, September 20, 2010 11:49:24 AM

Post# of 30387
Opportunity, I found this comment on trial costs. I would anticipate the lower side costs would be for a simple immunoassay using one time tests from a bank of samples.

If Moro intends to obtain FDA approval to do something like he presented at the ISOBM, then it would required extensive trials following specific breast cancer patients for a period up to a year and involve multiple testing. I seriously doubt if he would have the money for that but that's just my guess.


"Cost of Approval

The cost of clearing a device through the existing 510(k) program may range from less than $1 million to as much as $50 million, compared with $50 million to $150 million under a more- stringent FDA program for higher-risk devices such as heart pacemakers, Linda Alexander, an industry consultant at Alquest Inc. in Minneapolis, said in an interview."

GoldSeekerâ„¢

I have never shorted nor intend to have any financial interest in BOCX. I am not connected with anyone who trades, shorts or has financial interests in BOCX. I only post facts and my opinions. I do not post on IHUB with different aliases.

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.